Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Renal Cell

Explore clinical trials studying Carcinoma, Renal Cell. Study availability and eligibility vary by location and protocol.

1,363 public trials 252 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Renal Cell trial results

Active, Not Recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NCT03983954

Conditions
Adenocarcinoma, Adenocarcinoma Of Esophagus, Adenoma, +79 more
Locations
  • Shalby Hospital Ahmedabad, Gujarat, India
  • National Cancer Institute Jhajjar, Haryana, India
  • All India Institute of Medical Sciences New Delhi, India
  • PMCH (Pacific Medical College & Hospital) Udaipur, Rajasthan, India
View Trial Details
Active, Not Recruiting

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883

Conditions
Adenocarcinoma, Adenoma, Bronchial Neoplasms, +57 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, Not Recruiting

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

NCT06132945

Conditions
Adenocarcinoma, Brain Diseases, Brain Metastases, +21 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 6009) Chongqing, Chongqing Municipality, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036) Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Active, Not Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +47 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Local Institution Chicago, Illinois, United States
  • Local Institution - 0025 Buffalo, New York, United States
  • Local Institution - 0088 West Reading, Pennsylvania, United States
  • Local Institution - 0095 Capital Federal, Buenos Aires, Argentina
View all 89 locations
View Trial Details

Related conditions